title: Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.
abstract: The aim of this study was to design, develop, and optimize respirable tacrolimus microparticles and nanoparticles and multifunctional tacrolimus lung surfactant mimic particles for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced at different pump rates by advanced spray-drying particle engineering design from organic solution in closed mode. In addition, multifunctional tacrolimus lung surfactant mimic dry powder particles were prepared by co-dissolving tacrolimus and lung surfactant mimic phospholipids in methanol, followed by advanced co-spray-drying particle engineering design technology in closed mode. The lung surfactant mimic phospholipids were 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-[phosphor-rac-1-glycerol]. Laser diffraction particle sizing indicated that the particle size distributions were suitable for pulmonary delivery, whereas scanning electron microscopy imaging indicated that these particles had both optimal particle morphology and surface morphology. Increasing the pump rate percent of tacrolimus solution resulted in a larger particle size. X-ray powder diffraction patterns and differential scanning calorimetry thermograms indicated that spray drying produced particles with higher amounts of amorphous phase. X-ray powder diffraction and differential scanning calorimetry also confirmed the preservation of the phospholipid bilayer structure in the solid state for all engineered respirable particles. Furthermore, it was observed in hot-stage micrographs that raw tacrolimus displayed a liquid crystal transition following the main phase transition, which is consistent with its interfacial properties. Water vapor uptake and lyotropic phase transitions in the solid state at varying levels of relative humidity were determined by gravimetric vapor sorption technique. Water content in the various powders was very low and well within the levels necessary for dry powder inhalation, as quantified by Karl Fisher coulometric titration. Conclusively, advanced spray-drying particle engineering design from organic solution in closed mode was successfully used to design and optimize solid-state particles in the respirable size range necessary for targeted pulmonary delivery, particularly for the deep lung. These particles were dry, stable, and had optimal properties for dry powder inhalation as a novel pulmonary nanomedicine.
authors: University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences-Drug Development Division, Lexington, KY 40536-0596 , USA.
authors: Xiao
authors: X
authors: Wu
authors: Don
authors: D
authors: Hayes
authors: Joseph B
authors: JB
authors: Zwischenberger
authors: Robert J
authors: RJ
authors: Kuhn
authors: Heidi M
authors: HM
authors: Mansour
mesh_terms: D000280:Administration, Inhalation; D002626:Chemistry, Pharmaceutical; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems; D004355:Drug Stability; D058995:Dry Powder Inhalers; D006813:Humidity; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000737:chemistry; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D053758:Nanoparticles; D010316:Particle Size; D044367:Phase Transition; D010743:Phospholipids / Q000737:chemistry; D011663:Pulmonary Surfactants / Q000737:chemistry; D016559:Tacrolimus / Q000008:administration & dosage* / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods; D014961:X-Ray Diffraction
chemical_list: D007166:Immunosuppressive Agents; D010743:Phospholipids; D011663:Pulmonary Surfactants; D016559:Tacrolimus
keywords: dry powder inhaler (DPI); immunosuppression; lung surfactant; lung transplant; organic solution advanced spray drying; phospholipid colloidal self-assemblies; pulmonary nanomedicine; solid-state particle engineering design
references: Biochim Biophys Acta. 1998 Nov 19;1408(2-3):79-89
references: 9813251
references: Int J Pharm. 2008 May 1;355(1-2):277-84
references: 18243606
references: Pharm Res. 1999 Mar;16(3):350-8
references: 10213364
references: Adv Drug Deliv Rev. 2012 Mar 30;64(4):344-56
references: 21920394
references: Nephrologie. 1992;13(3):137
references: 1379348
references: J Pharm Sci. 2010 Feb;99(2):587-97
references: 19862804
references: Transplant Proc. 2010 Nov;42(9):3876-9
references: 21094875
references: Nat Rev Drug Discov. 2007 Jan;6(1):67-74
references: 17195033
references: Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):56-61
references: 7529414
references: Transplant Proc. 2007 Sep;39(7):2416-9
references: 17889206
references: Curr Opin Immunol. 1992 Oct;4(5):548-52
references: 1384551
references: J Pharm Sci. 2010 Aug;99(8):3415-29
references: 20222025
references: J Pharm Sci. 2010 Aug;99(8):3398-414
references: 20198688
references: Eur Respir J. 1997 Nov;10(11):2630-7
references: 9426106
references: J Cardiothorac Surg. 2011 Jul 18;6:92
references: 21767391
references: Transpl Infect Dis. 2012 Oct;14(5):548-50
references: 22650803
references: Eur Respir J. 2003 Dec;22(6):1007-18
references: 14680094
references: J Pharm Sci. 2007 Feb;96(2):377-96
references: 17080427
references: J Heart Lung Transplant. 2007 Aug;26(8):782-95
references: 17692782
references: J Heart Lung Transplant. 2006 Apr;25(4):434-9
references: 16563974
references: Int J Nanomedicine. 2009;4:299-319
references: 20054434
references: Biophys J. 2007 Jul 1;93(1):164-75
references: 17434940
references: Eur Respir J. 2004 Jan;23(1):159-71
references: 14738248
references: Cell Immunol. 1991 Feb;132(2):285-94
references: 1703047
references: Langmuir. 2007 Mar 27;23(7):3809-19
references: 17323986
references: Thorax. 1999 Jun;54(6):550-3
references: 10335012
references: J Heart Lung Transplant. 2002 Mar;21(3):297-310
references: 11897517
references: Pharm Res. 2005 Jan;22(1):148-52
references: 15771241
references: Lung. 2012 Jun;190(3):251-62
references: 22274758
references: Int J Nanomedicine. 2013;8:275-93
references: 23355776
references: AAPS PharmSciTech. 2011 Dec;12(4):1420-30
references: 22038473
references: Eur Respir J. 2004 Mar;23(3):384-90
references: 15065826
references: Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1119-27
references: 16997418
references: Transplant Proc. 1997 Feb-Mar;29(1-2):79-81
references: 9123164
references: Pharm Dev Technol. 1997 Aug;2(3):213-23
references: 9552449
references: Mol Pharm. 2008 Sep-Oct;5(5):681-95
references: 18630875
references: Comp Biochem Physiol A Mol Integr Physiol. 2001 May;129(1):65-73
references: 11369534
references: J Antibiot (Tokyo). 1987 Sep;40(9):1249-55
references: 2445721
references: Biochemistry. 2004 Aug 3;43(30):9926-38
references: 15274647
references: Biochim Biophys Acta. 1998 Nov 19;1408(2-3):90-108
references: 9813256
references: J Hepatol. 1993 Mar;17(3):301-7
references: 7686193
references: Pharm Res. 2001 Nov;18(11):1570-7
references: 11758765
references: J Heart Lung Transplant. 2007 Aug;26(8):769-81
references: 17692781
references: J Pharm Sci. 2010 Aug;99(8):3430-41
references: 20229601
references: Thorac Cardiovasc Surg. 1999 Jun;47(3):174-8
references: 10443520
references: Ann N Y Acad Sci. 1993 Nov 30;696:9-19
references: 7509138
references: Crit Rev Ther Drug Carrier Syst. 1997;14(4):395-453
references: 9450176
references: J Heart Lung Transplant. 1996 Jan;15(1 Pt 1):1-15
references: 8820078
references: J Pharm Sci. 2007 May;96(5):1282-301
references: 17455324
references: Nephrol Dial Transplant. 2000 Dec;15(12):1916-8
references: 11096132
references: Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):88-109
references: 20950661